Tenon Medical Files 8-K on Equity Sales

TL;DR

Tenon Medical just filed an 8-K for unregistered equity sales - watch for dilution!

AI Summary

Tenon Medical, Inc. entered into a material definitive agreement on November 10, 2025, related to unregistered sales of equity securities. The company, incorporated in Delaware, filed this 8-K report on November 17, 2025, detailing these events. The filing also includes financial statements and exhibits.

Why It Matters

This filing indicates potential dilution or capital raising activities for Tenon Medical, which could impact existing shareholders and the company's financial structure.

Risk Assessment

Risk Level: medium — Unregistered equity sales can signal financial distress or dilution, requiring careful examination of the terms and potential impact.

Key Players & Entities

• Tenon Medical, Inc. (company) — Registrant
• November 10, 2025 (date) — Earliest event reported
• November 17, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share TNON The Nasdaq Stock Mar
• $1.285 — ompany, at a combined offering price of $1.285 per Share and Warrant to purchase one s
• $1.16 — The Warrants have an exercise price of $1.16 per share and expire 3 years from the d
• $2.85 million — any. The Company received approximately $2.85 million in gross proceeds of the offering, whic

Filing Documents

• ea0265746-8k_tenon.htm (8-K) — 38KB
• ea026574601ex4-1_tenon.htm (EX-4.1) — 67KB
• ea026574601ex4-2_tenon.htm (EX-4.2) — 68KB
• ea026574601ex10-1_tenon.htm (EX-10.1) — 343KB
• ea026574601ex99-1_tenon.htm (EX-99.1) — 11KB
• ea026574601ex99-2_tenon.htm (EX-99.2) — 11KB
• 0001213900-25-111522.txt ( ) — 878KB
• tnon-20251110.xsd (EX-101.SCH) — 4KB
• tnon-20251110_def.xml (EX-101.DEF) — 26KB
• tnon-20251110_lab.xml (EX-101.LAB) — 36KB
• tnon-20251110_pre.xml (EX-101.PRE) — 25KB
• ea0265746-8k_tenon_htm.xml (XML) — 5KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On November 10, 2025, Tenon Medical, Inc., a Delaware corporation (the "Company"), entered into securities purchase agreements (the "Purchase Agreements") with certain accredited investors (the "Purchasers") pursuant to which the Company agreed to issue and sell an aggregate of 2,217,904 shares of common stock, par value $0.001 per share (the "Shares"), and/or pre-funded common stock purchase warrants ("Pre-Funded Warrants"), and common stock purchase warrants (the "Warrants"), each exercisable for one share of common stock of the Company, at a combined offering price of $1.285 per Share and Warrant to purchase one share of common stock. The Warrants have an exercise price of $1.16 per share and expire 3 years from the date of issuance. The Purchase Agreement contained customary representations and warranties. The Shares and the shares underlying the Warrants are entitled to customary resale registration rights. The offering closed on November 14, 2025, and the Company issued Purchasers an aggregate 2,217,904 Shares and Warrants to purchase 2,217,904 shares of common stock of the Company. The Company received approximately $2.85 million in gross proceeds of the offering, which it intends to use for working capital and general corporate purposes. Steven Foster, the Company's Chief Executive Officer and Director, Nathaniel Grawey, the Company's Chief Commercial Officer, and Wyatt Geist, the Company's Chief Innovation Officer, participated in the offering as Purchasers. Under the Purchase Agreement the Company is required to file a registration statement in respect of the Shares and the shares underlying the Warrants within 30 days after the date of the Purchase Agreement. The issuance of the Shares and Warrants pursuant to the Purchase Agreements was made pursuant to the exemption from the registration requirements under the Securities Act available to the Company under Section 4(a)(2) and/or Regulation D pr

02 Unregistered

Item 3.02 Unregistered Sales of Equity Securities. The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The Company offered and sold the Shares, Pre-Funded Warrants and Warrants to the Purchasers in reliance on the exemption from registration provided by Section 4(a)(2) and Regulation 506(b) under the Securities Act of 1933, as amended.

01. Other Information

Item 8.01. Other Information. On November 11, 2025, the Company issued a press release announcing the pricing of the offering described above. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. On November 14, 2025, the Company issued a press release announcing the closing of the offering described above. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth in this Item 8.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. 1

01 Financial

Item 9.01 Financial (d) Exhibits The following exhibits are filed herewith: Exhibit No. Description 4.1 Form of Common Stock Purchase Warrant, dated November 13, 2025 4.2 Form of Pre-Funded Common Stock Purchase Warrant 10.1* Form of Securities Purchase Agreement, dated November 10, 2025, between Tenon Medical Inc. and Purchasers 99.1 Press release issued by Tenon Medical, Inc., dated November 11, 2025 99.2 Press release issued by Tenon Medical, Inc., dated November 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Schedules and similar attachments have been omitted pursuant to Regulation S-K Item 601(a)(5). The Company agrees to furnish a supplemental copy of any omitted schedule or attachment to the SEC upon request. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 17, 2025 TENON MEDICAL, INC. (Registrant) By: /s/ Steven M. Foster Name: Steven M. Foster Title: Chief Executive Officer and President 3

View Full Filing

View this 8-K filing on SEC EDGAR